Becton Dickinson and Co (BDX)
Valor JustoFundamental
60
Precio
$179.00
Capitalización Bursátil
$50.07B
Parte 1 · Cuánto vale la empresa
Resumen
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 de septiembre de 2026 with claude-haiku-4-5 — shared with all users
Baxter sells infusion pumps, IV sets and injectable drug delivery systems to the same hospital pharmacies and purchasing groups that buy BD's medication delivery and infusion business.
After absorbing Hospira's infusion business, ICU Medical bids against BD for hospital contracts on infusion pumps, IV sets and vascular access consumables.
Abbott competes with BD's Life Sciences arm for hospital laboratory budgets, supplying diagnostic instruments and infectious-disease testing systems to the same clinical labs.
This family-owned German group competes with BD across the whole IV therapy line — catheters, infusion pumps, syringes and needles — in hospitals in Europe and the United States.
Teleflex competes head-on with BD's interventional and vascular access catalogue, above all central venous and PICC catheters bought by the same hospital departments.
Medtronic overlaps with BD on needles and syringes and on vascular and urology intervention devices sold to the same surgical and interventional specialists.
Balance y Liquidez
Ingresos
$22.41B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$941M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$2.67B
Patrimonio Neto Total
$25.39B
Pasivo Total
$29.93B
Ratio de Liquidez
0.87
Cobertura de Intereses
3.92
Deuda/EBITDA
3.33
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$216.42
Precio Actual
$179.00
Margen de Seguridad
+17.3%
Rango de Valor Justo
$140.67 - $292.17
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
54.08
ROE
6.6%
Ratio P/B
2.00
P/FCF
15.22
Margen Bruto
46.7%
ROIC
4.4%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
4.4%
WACC
6.7%
ROIC − WACC
-2.3 pp
El ROIC está por debajo del coste del capital: la empresa destruye valor por cada dólar invertido.
Criterios de Análisis Fundamental
Superado (17)
- EPS shows upward trend
- Gross Margin 46.7%
- P/FCF 15.22
- P/B Ratio 2.00
- Debt/Equity ratio
- Operating Margin 10.3%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 6.3%
- Analyst Consensus 57% Buy
- Earnings Quality (OCF/NI) 4.20
- Share Dilution -0.9%
- Piotroski F-Score 8/9
Fallido (10)
- EPS CAGR 2.88%
- Price CAGR 3.43%
- ROIC 4.4%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.8%
- Earnings Surprise avg 1.9%
- PEG Ratio 3.94
- Net Margin Trend 4.2% vs 8.0%
No disponible (1)
- Dividend Payout NaN%
Piotroski F-Score
Solidez financiera fuerte
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Participaciones institucionales
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Thomas E. Polen Jr. | President, CEO & Chairman | 52 |
| Dr. Michael D. Garrison | Executive VP & President of Medical Segment and BioPharma Systems Segments | 55 |
| Mr. Michael C. Feld | Executive VP & Chief Revenue Officer | 44 |
| Mr. Vitor Roque | Executive VP & CFO | 42 |
| Ms. Elizabeth McCombs | Executive VP & CTO | 48 |
| Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. | Senior VP & Chief Scientific Officer | - |
| Ms. Denise Russell Fleming | Executive Vice President & Chief Information Officer | 54 |
| Mr. Shawn C. Bevec | Senior Vice President of Investor Relations | - |
| Ms. Lanesha T. Minnix J.D. | Executive VP & General Counsel | 50 |
| Carla Burigatto | Senior VP & Chief Communications Officer | - |
Riesgo de Auditoría
3
Riesgo del Consejo
6
Riesgo de Compensación
5
Riesgo de Derechos del Accionista
1
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Documentos
- Ver documento
Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2025-11-25
- Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-08-06
- Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-08-06
via SEC EDGAR
Historial de Resultados
via SEC EDGAR
Latest News
Recent headlines for BDX, sourced from Markets Gazette.